<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CLINDAMYCIN- clindamycin phosphateÂ injection, solutionÂ </strong><br>APP Pharmaceuticals, LLC<br></p></div>
<h1>Clindamycin Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e8b42508-c46e-4aca-b586-14245e05f86a"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">Rx only</p>
<table>
<colgroup><col align="left"></colgroup>
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="left">
<span class="Bold"><span class="Emphasis">PHARMACY BULK PACKAGE -</span></span><p class="First"><span class="Bold"><span class="Emphasis">NOT FOR DIRECT INFUSION</span></span></p>
</td></tr></tbody>
</table>
<p><span class="Bold"><span class="Emphasis">For Intravenous Use</span></span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin Injection, USP and other antibacterial drugs, Clindamycin Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Warning">
<a name="cbab2650-699c-4c34-b6a5-d4730273cad4"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"></p>
<p><span class="Bold"><span class="Emphasis">WARNING</span></span></p>
<p><span class="Italics"><span class="Emphasis">Clostridium difficile </span></span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Clindamycin Injection, USP and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.Â  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics"><span class="Emphasis">C. difficile</span></span>.</p>
<p>Because clindamycin therapy has been associated with severe <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> which may end fatally, it should be reserved for serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> where less toxic antimicrobial agents are inappropriate, as described in the <span class="Bold"><span class="Emphasis"><a href="#b34bcea3-334f-44bc-bf36-49d1a7455973">INDICATIONS AND USAGE </a></span></span>section.Â  It should not be used in patients with nonbacterial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> such as most <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>.Â  <span class="Italics"><span class="Emphasis">C. difficile </span></span>produces toxins A and B which contribute to the development of CDAD.Â  Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">C. difficile </span></span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy.Â  CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use.Â  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics"><span class="Emphasis">C. difficile </span></span>may need to be discontinued.Â  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics"><span class="Emphasis">C. difficile</span></span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p></p>
<br>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="a43783a0-93dc-4551-b829-554bea7d4911"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Clindamycin Injection, USP for intravenous use, contains clindamycin phosphate, a water soluble ester of clindamycin and phosphoric acid.Â  Each mL contains clindamycin phosphate equivalent to 150 mg clindamycin, 0.5 mg disodium edetate and 9.45 mg benzyl alcohol added as preservative.Â  When necessary, pH is adjusted with sodium hydroxide and/or hydrochloric acid.Â  Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent compound lincomycin.Â Â Â Â Â Â Â Â Â Â Â </p>
<p>The chemical name of clindamycin phosphate is L-<span class="Italics"><span class="Emphasis">threo</span></span>-Î±-D-<span class="Italics"><span class="Emphasis">galacto</span></span>-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl] amino]-1-thio-, 2-(dihydrogen phosphate), (2<span class="Italics"><span class="Emphasis">S</span></span>-<span class="Italics"><span class="Emphasis">trans</span></span>)-.</p>
<p>The structural formula is represented below:</p>
<p></p>
<p><img alt="clindamycin-structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd1c1648-4733-4233-8337-469fe11bd0cb&amp;name=clindamycin-injection-usp-(pbp)-figure-1.jpg">Â </p>
<br><p>A pharmacy bulk package is a container of a sterile preparation for intravenous use that contains many single doses.Â  The contents are intended for use in a pharmacy admixture program utilizing a sterile transfer device and are restricted to the preparation of admixtures for intravenous infusion.Â  <span class="Bold"><span class="Emphasis">FURTHER DILUTION IS REQUIRED BEFORE USE</span></span> (see <span class="Bold"><span class="Emphasis"><a href="#b2f2fb2f-3db8-489a-a444-8eb2208097ba">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="b68c8c06-5654-416b-81ea-7734131604e2"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Biologically inactive clindamycin phosphate is rapidly converted to active clindamycin.</p>
<p>By the end of short-term intravenous infusion, peak serum levels of active clindamycin are reached.Â  Biologically inactive clindamycin phosphate disappears rapidly from the serum; the average elimination half-life is 6 minutes; however, the serum elimination half-life of active clindamycin is about 3 hours in adults and 2Â½ hours in pediatric patients. </p>
<p>Serum levels of clindamycin can be maintained above the <span class="Italics"><span class="Emphasis">in vitro </span></span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> for most indicated organisms by administration of clindamycin phosphate every 8 to 12 hours in adults and every 6 to 8 hours in pediatric patients, or by continuous intravenous infusion.Â  An equilibrium state is reached by the third dose.</p>
<p>The elimination half-life of clindamycin is increased slightly in patients with markedly reduced renal or hepatic function.Â  Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.Â  Dosage schedules need not be modified in the presence of mild or moderate renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.</p>
<p>No significant levels of clindamycin are attained in the cerebrospinal fluid even in the presence of inflamed meninges.</p>
<p>Pharmacokinetic studies in elderly volunteers (61 to 79 years) and younger adults (18 to 39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate.Â  After oral administration of clindamycin hydrochloride, elimination half-life is increased to approximately 4 hours (range 3.4 to 5.1 h) in the elderly compared to 3.2 hours (range 2.1 to 4.2 h) in younger adults.Â  The extent of absorption, however, is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function<span class="Sup">1</span>. </p>
<p>Serum assays for active clindamycin require an inhibitor to prevent <span class="Italics"><span class="Emphasis">in vitro</span></span> hydrolysis of clindamycin phosphate.</p>
<p><span class="Bold"><span class="Emphasis">Table 1.Â Â  Average Peak and Trough Serum Concentrations of Active</span></span></p>
<p><span class="Bold"><span class="Emphasis">Clindamycin After Dosing with Clindamycin Phosphate</span></span></p>
<table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">Â </span></span></p>
<p><span class="Bold"><span class="Emphasis">Dosage Regimen</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">Peak</span></span></p>
<p><span class="Bold"><span class="Emphasis">mcg/mL</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">Trough</span></span></p>
<p><span class="Bold"><span class="Emphasis">mcg/mL</span></span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">Healthy Adult Males (Post equilibrium)</span></span></p>
<p>Â  600 mg IV in 30 min q6h</p>
<p>Â  600 mg IV in 30 min q8h</p>
<p>Â  900 mg IV in 30 min q8h</p>
<p>Â  <span class="Bold"><span class="Emphasis">Pediatric Patients (first dose)*</span></span></p>
<p><span class="Bold"><span class="Emphasis">Â  </span></span>5 to 7 mg/kg IV in 1 hour<span class="Bold"><span class="Emphasis">Â  </span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<br><p class="First">10.9</p>
<p>10.8</p>
<p>14.1</p>
<br><p>10</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<br><p class="First">2</p>
<p>1.1</p>
<p>1.7</p>
<br><p>â€”</p>
</td>
</tr>
</tbody>
</table>
<p>*Data in this group from patients being treated for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="a49d61c1-dd31-4956-9ab1-1d357ccd2984"></a><a name="section-3.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Although clindamycin phosphate is inactive <span class="Italics"><span class="Emphasis">in vitro</span></span>, rapid <span class="Italics"><span class="Emphasis">in vivo</span></span> hydrolysis converts this compound to the antibacterially active clindamycin.</p>
<p>Clindamycin has been shown to have <span class="Italics"><span class="Emphasis">in vitro</span></span> activity against isolates of the following organisms:</p>
<p><span class="Italics"><span class="Emphasis">Aerobic gram positive cocci</span></span>, including:</p>
<ul>
<li>Â Staphylococcus aureus (penicillinase and non-penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).Â  When tested by <span class="Italics"><span class="Emphasis">in vitro</span></span> methods, some staphylococcal <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> originally resistant to erythromycin rapidly develop resistance to clindamycin.</li>
<li>Â Staphylococcus epidermidis (penicillinase and non-penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).Â  When tested by <span class="Italics"><span class="Emphasis">in vitro</span></span> methods, some staphylococcal <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> originally resistant to erythromycin rapidly develop resistance to clindamycin.</li>
<li>Â Streptococci (except <span class="Italics"><span class="Emphasis">Enterococcus</span></span><span class="Italics"><span class="Emphasis">faecalis</span></span>)</li>
<li>Â Pneumococci</li>
</ul>
<p><span class="Italics"><span class="Emphasis">Anaerobic gram negative bacilli</span></span>, including:</p>
<ul>
<li>
<span class="Italics"><span class="Emphasis">Bacteroides </span></span>species (including <span class="Italics"><span class="Emphasis">Bacteroides fragilis</span></span> group and <span class="Italics"><span class="Emphasis">Bacteroides </span></span><span class="Italics"><span class="Emphasis">melaninogenicus</span></span> group)</li>
<li>Â <span class="Italics"><span class="Emphasis">Fusobacterium</span></span> species</li>
</ul>
<p><span class="Italics"><span class="Emphasis">Anaerobic gram positive nonsporeforming bacilli</span></span>, including:</p>
<ul>
<li>Â <span class="Italics"><span class="Emphasis">Propionibacterium</span></span>
</li>
<li>Â <span class="Italics"><span class="Emphasis">Eubacterium</span></span>
</li>
<li>Â <span class="Italics"><span class="Emphasis">Actinomyces</span></span> species</li>
</ul>
<p><span class="Italics"><span class="Emphasis">Anaerobic </span></span>and<span class="Italics"><span class="Emphasis"> microaerophilic gram positive cocci</span></span>, including:</p>
<ul>
<li>Â <span class="Italics"><span class="Emphasis">Peptococcus</span></span> species</li>
<li>Â <span class="Italics"><span class="Emphasis">Peptostreptococcus</span></span> species</li>
<li>Â Microaerophilic streptococci</li>
</ul>
<p>Clostridia: Clostridia are more resistant than most anaerobes to clindamycin. Most <span class="Italics"><span class="Emphasis">Clostridium perfringens</span></span> are susceptible, but other species, e.g., <span class="Italics"><span class="Emphasis">Clostridium sporogenes</span></span> and <span class="Italics"><span class="Emphasis">Clostridium tertium</span></span> are frequently resistant to clindamycin.Â  Susceptibility testing should be done.</p>
<p>Cross resistance has been demonstrated between clindamycin and lincomycin.</p>
<p>Antagonism has been demonstrated between clindamycin and erythromycin.</p>
<p><span class="Bold Italics"><span class="Emphasis"><span class="Bold Italics"><span class="Emphasis">In vitro</span></span></span></span><span class="Bold"><span class="Emphasis"> Susceptibility Testing:</span></span><span class="Bold Italics"><span class="Emphasis"></span></span></p>
<p><span class="Underline"><span class="Emphasis">Disk diffusion technique</span></span> - Quantitative methods that require measurement of zone diameters give the most precise estimates of antibiotic susceptibility.Â  One such procedure<span class="Sup">2 </span>has been recommended for use with disks to test susceptibility to clindamycin.</p>
<p>Reports from a laboratory using the standardized single-disk susceptibility test<span class="Sup">1</span> with a 2 mcg clindamycin disk should be interpreted according to the following criteria:Â </p>
<p>Susceptible organisms produce zones of 17 mm or greater, indicating that the tested organism is likely to respond to therapy.</p>
<p>Organisms of intermediate susceptibility produce zones of 15 to 16 mm, indicating that the tested organism would be susceptible if a high dosage is used or if the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confined to tissues and fluids (e.g., urine), in which high antibiotic levels are attained.</p>
<p>Resistant organisms produce zones of 14 mm or less, indicating that other therapy should be selected.Â Â </p>
<p>Standardized procedures require the use of control organisms. Â The 2 mcg clindamycin disk should give a zone diameter between 24 and 30 mm for <span class="Italics"><span class="Emphasis">S</span></span>. <span class="Italics"><span class="Emphasis">aureus </span></span>ATCC 25923.Â Â Â Â Â Â Â Â  </p>
<p><span class="Underline"><span class="Emphasis">Dilution techniques</span></span> â€“ A bacterial isolate may be considered susceptible if the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) for clindamycin is not more than 1.6 mcg/mL.Â  Organisms are considered moderately susceptible if the MIC is greater than 1.6 mcg/mL and less than or equal to 4.8 mcg/mL.Â  Organisms are considered resistant if the MIC is greater than 4.8 mcg per mL.</p>
<p>The range of MICs for the control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are as follows:</p>
<p><span class="Italics"><span class="Emphasis">Â Â Â Â Â  S. aureus</span></span> ATCC 29213, 0.06 to 0.25 mcg/mL. </p>
<p><span class="Italics"><span class="Emphasis">Â Â Â Â Â  E. faecalis</span></span> ATCC 29212, 4 to 16 mcg/mL.</p>
<p>For anaerobic bacteria the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) of clindamycin can be determined by agar dilution and broth dilution (including microdilution) techniques.<span class="Sup">3Â  </span>If MICs are not determined routinely, the disk broth method is recommended for routine use.Â  THE KIRBY-BAUER DISK DIFFUSION METHOD AND ITS INTERPRETIVE STANDARDS ARE NOT RECOMMENDED FOR ANAEROBES.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b34bcea3-334f-44bc-bf36-49d1a7455973"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin Injection, USP and other antibacterial drugs, Clindamycin Injection, USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.Â  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.Â  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>Clindamycin Injection, USP is indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible anaerobic bacteria.</p>
<p>Clindamycin Injection, USP is also indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate.Â  Because of the risk of antibiotic-associated <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, as described in the <span class="Bold"><span class="Emphasis">WARNING</span></span> box, before selecting clindamycin the physician should consider the nature of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the suitability of less toxic alternatives (e.g., erythromycin).</p>
<p>Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.</p>
<p>Indicated surgical procedures should be performed in conjunction with antibiotic therapy.</p>
<p>Clindamycin Injection, USP is indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the conditions listed below:</p>
<p><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower respiratory tract infections</span> including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4209859" conceptname="Empyema">empyema</span>, and <span class="product-label-link" type="condition" conceptid="257010" conceptname="Abscess of lung">lung abscess</span> caused by anaerobes, <span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span>, other streptococci (except <span class="Italics"><span class="Emphasis">E. faecalis</span></span>), and <span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span>.</p>
<p>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by <span class="Italics"><span class="Emphasis">Streptococcus pyogenes</span></span>, <span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span>, and anaerobes.</p>
<p>Gynecological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> including <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span>, nongonococcal tubo-ovarian <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, pelvic <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, and postsurgical vaginal cuff <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by susceptible anaerobes.</p>
<p>Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> including <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> and intra-<span class="product-label-link" type="condition" conceptid="4326255" conceptname="Abdominal abscess">abdominal abscess</span> caused by susceptible anaerobic organisms.</p>
<p><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span> caused by <span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span>, streptococci (except <span class="Italics"><span class="Emphasis">Enterococcus faecalis</span></span>), and susceptible anaerobes.</p>
<p>Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span> including acute hematogenous <span class="product-label-link" type="condition" conceptid="141663" conceptname="Osteomyelitis">osteomyelitis</span> caused by <span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span> and as adjunctive therapy in the surgical treatment of chronic bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span> due to susceptible organisms.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="e8dd43d6-761e-4567-980d-d5a452db0a0f"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This drug is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to preparations containing clindamycin or lincomycin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="b518afe4-e60a-4871-99c4-a70079ab79ce"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <span class="Bold"><span class="Emphasis">WARNING</span></span> box.</p>
<p><span class="Italics"><span class="Emphasis">Clostridium difficile </span></span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin injection and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.Â  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics"><span class="Emphasis">C. difficile</span></span>.</p>
<p><span class="Italics"><span class="Emphasis">C. difficile </span></span>produces toxins A and B which contribute to the development of CDAD. Â Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics"><span class="Emphasis">C. difficile </span></span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. Â CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Â Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics"><span class="Emphasis">C. difficile </span></span>may need to be discontinued. Â Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics"><span class="Emphasis">C. difficile</span></span>, and surgical evaluation should be instituted as clinically indicated. </p>
<p>A careful inquiry should be made concerning previous sensitivities to drugs and other allergens.</p>
<p>This product contains benzyl alcohol as a preservative. Â Benzyl alcohol has been associated with a fatal â€œGasping Syndromeâ€? in premature infants (see <span class="Bold"><span class="Emphasis"><a href="#c09edf66-be38-4b45-ad91-feb1968f9620">PRECAUTIONS, Pediatric Use</a></span></span>).Â  </p>
<p><span class="Italics"><span class="Emphasis">Usage in <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> </span></span>â€“ Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>.</p>
<p>SERIOUS <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">ANAPHYLACTOID REACTIONS</span> REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN AND INTRAVENOUS CORTICOSTEROIDS SHOULD ALSO BE ADMINISTERED AS INDICATED.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="c09edf66-be38-4b45-ad91-feb1968f9620"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="e4fcad68-1c12-4978-9fb0-211d83401cbf"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> less well.Â  When clindamycin is indicated in these patients, they should be carefully monitored for change in bowel frequency.</p>
<p>Clindamycin should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>Clindamycin should be prescribed with caution in <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopic</span> individuals. </p>
<p>Certain <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may require incision and drainage or other indicated surgical procedures in addition to antibiotic therapy.</p>
<p>The use of clindamycin may result in overgrowth of nonsusceptible organisms â€“ particularly yeasts.Â  Should <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> occur, appropriate measures should be taken as indicated by the clinical situation.</p>
<p>Clindamycin should not be injected intravenously undiluted as a bolus, but should be infused over at least 10 to 60 minutes as directed in <span class="Bold"><span class="Emphasis"><a href="#b2f2fb2f-3db8-489a-a444-8eb2208097ba">DOSAGE AND ADMINISTRATION</a><span class="Bold"><span class="Emphasis"></span></span></span></span>section.</p>
<p>Clindamycin dosage modification may not be necessary in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.Â  In patients with moderate to severe liver disease, prolongation of clindamycin half-life has been found.Â  However, it was postulated from studies that when given every eight hours, accumulation should rarely occur.Â  Therefore, dosage modification in patients with liver disease may not be necessary.Â  However, periodic liver enzyme determinations should be made when treating patients with severe liver disease.</p>
<p>Prescribing clindamycin in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="e00ba31b-33e6-4627-926e-32ac9ad803b4"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients<br>
</h2>
<p class="First">Patients should be counseled that antibacterial drugs including clindamycin injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.Â  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).Â  When clindamycin injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.Â  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by clindamycin injection or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.Â  Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic.Â  If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d2169ea6-9122-4775-a8a1-e35889659926"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests<br>
</h2>
<p class="First">During prolonged therapy periodic liver and kidney function tests and blood counts should be performed.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f85414ea-e0e0-4374-a416-007eaefdfabf"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents.Â  Therefore, it should be used with caution in patients receiving such agents.</p>
<p>Antagonism has been demonstrated between clindamycin and erythromycin <span class="Italics"><span class="Emphasis">in vitro</span></span>.Â  Because of possible clinical significance, the two drugs should not be administered concurrently.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fdf4c656-b275-41c7-b409-b332ed3dd2bb"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility<br>
</h2>
<p class="First">Long-term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential.Â  Genotoxicity tests performed included a rat micronucleus test and an Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> reversion test. Both tests were negative.</p>
<p>Fertility studies in rats treated orally with up to 300 mg/kg/day (approximately 1.1 times the highest recommended adult human dose based on mg/m<span class="Sup">2</span>) revealed no effects on fertility or mating ability.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b9015fbe-5319-4984-87b6-8b382f8f313d"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy: Teratogenic Effects<br>
</h2>
<p class="First">Pregnancy Category B</p>
<p>Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (2.1 and 1.1 times the highest recommended adult human dose based on mg/m<span class="Sup">2</span>, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (0.9 and 0.5 times the highest recommended adult human dose based on mg/m<span class="Sup">2</span>, respectively) revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>.</p>
<p>There are, however, no adequate and well-controlled studies in pregnant women.Â  Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="efc83e45-39fb-47ce-8fc8-4fd04538d044"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">Clindamycin has been reported to appear in breast milk in the range of 0.7 to 3.8 mcg/mL at dosages of 150 mg orally to 600 mg intravenously.Â  Because of the potential for adverse reactions due to clindamycin in neonates (see <span class="Bold Italics"><span class="Emphasis"><a href="#c09edf66-be38-4b45-ad91-feb1968f9620">Pediatric Use</a></span></span>), the decision to discontinue the drug should be made, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="cea2a2c2-6acb-4141-b515-8c29240f4d47"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use<br>
</h2>
<p class="First">When clindamycin is administered to the pediatric population (birth to 16 years) appropriate monitoring of organ system functions is desirable.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ce44e055-04a5-4d65-88d0-f2907fdcdd16"></a><a name="section-7.9"></a><p></p>
<h2>Usage in Newborns and Infants<br>
</h2>
<p class="First">This product contains benzyl alcohol as a preservative.Â  Benzyl alcohol has been associated with a fatal â€œGasping Syndromeâ€? in premature infants.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d1fd3bd6-7781-4fa7-b4d2-b000dff7fda4"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use<br>
</h2>
<p class="First">Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. Â However, other reported clinical experience indicates that antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (due to <span class="Italics"><span class="Emphasis">Clostridium difficile</span></span>) seen in association with most antibiotics occur more frequently in the elderly (&gt;60 years) and may be more severe. Â These patients should be carefully monitored for the development of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Pharmacokinetic studies with clindamycin have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration.</p>
<br>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ca54086c-6fac-4fc5-932e-2782fa29be59"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following reactions have been reported with the use of clindamycin.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="ef3032a6-99f2-432a-b1bb-f1605f607c86"></a><a name="section-8.1"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Antibiotic-associated <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> (see <span class="Bold"><span class="Emphasis"><a href="#b518afe4-e60a-4871-99c4-a70079ab79ce">WARNINGS</a></span></span>), <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.Â  The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibacterial treatment (see <span class="Bold"><span class="Emphasis"><a href="#b518afe4-e60a-4871-99c4-a70079ab79ce">WARNINGS</a></span></span>).Â  An unpleasant or metallic taste occasionally has been reported after intravenous administration of the higher doses of clindamycin phosphate.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a6a000e7-6367-4cb8-a02c-f652012e174f"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span><br>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">Maculopapular rash</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been observed during drug therapy.Â  Generalized mild to moderate morbilliform-like <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> are the most frequently reported of all adverse reactions.Â  Rare instances of <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, some resembling <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, have been associated with clindamycin.Â  A few cases of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported.Â  If a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> occurs, the drug should be discontinued.Â  The usual agents (epinephrine, corticosteroids, antihistamines) should be available for emergency treatment of serious reactions.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d36bf672-2f84-46a4-8066-a7547d01bf4e"></a><a name="section-8.3"></a><p></p>
<h2>Skin and Mucous Membranes<br>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, and rare instances of <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> have been reported (see <span class="Bold Italics"><span class="Emphasis"><a href="#ca54086c-6fac-4fc5-932e-2782fa29be59"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="b3b03453-f456-4d2f-bf6f-77523dad63c8"></a><a name="section-8.4"></a><p></p>
<h2>Liver</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> and abnormalities in liver function tests have been observed during clindamycin therapy.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="acc692e9-ee3d-42ae-aa80-1cc640fddec0"></a><a name="section-8.5"></a><p></p>
<h2>Renal</h2>
<p class="First">Although no direct relationship of clindamycin to renal damage has been established, renal dysfunction as evidenced by <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and/or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> has been observed in rare instances.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="f7980701-4838-4b59-942a-1b2ec8ee32b0"></a><a name="section-8.6"></a><p></p>
<h2>Hematopoietic</h2>
<p class="First">Transient <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>) and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been reported.Â  Reports of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> have been made.Â  No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ed6f49d0-7f40-407a-9175-fc9440dfcf1b"></a><a name="section-8.7"></a><p></p>
<h2>Local Reactions<br>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> and sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> have been reported after intramuscular injection and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> after intravenous infusion.Â  Reactions can be minimized or avoided by giving deep intramuscular injections and avoiding prolonged use of indwelling intravenous catheters.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="a2856e7b-b293-4921-b516-6ed203dc2a20"></a><a name="section-8.8"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First">Rare instances of <span class="product-label-link" type="condition" conceptid="4025831" conceptname="Arthritis mutilans">polyarthritis</span> have been reported.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="fc29d407-2a79-4b77-8871-8bf0178b5f4a"></a><a name="section-8.9"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First">Rare instances of <span class="product-label-link" type="condition" conceptid="4256374" conceptname="Cardiorespiratory arrest">cardiopulmonary arrest</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> have been reported following too rapid intravenous administration (see <span class="Bold"><span class="Emphasis"><a href="#b2f2fb2f-3db8-489a-a444-8eb2208097ba">DOSAGE AND ADMINISTRATION</a><span class="Bold"><span class="Emphasis">Â </span></span></span></span>section).</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="a129299f-8568-4565-a502-4f0f1ab31a46"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Significant mortality was observed in mice at an intravenous dose of 855 mg/kg and in rats at an oral or subcutaneous dose of approximately 2618 mg/kg.Â  In the mice, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> were observed.</p>
<p>Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b2f2fb2f-3db8-489a-a444-8eb2208097ba"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs during therapy, this antibiotic should be discontinued (see <span class="Bold"><span class="Emphasis">WARNING </span></span>box).</p>
<div class="Section" data-sectionCode="34068-7">
<a name="b38b1c7e-b167-4ddf-9b0a-648b0fa493a7"></a><a name="section-10.1"></a><p></p>
<h2>Adults</h2>
<p class="First">Parenteral IV administration</p>
<p>Serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including <span class="Italics"><span class="Emphasis">Bacteroides fragilis</span></span>, <span class="Italics"><span class="Emphasis">Peptococcus</span></span> species and <span class="Italics"><span class="Emphasis">Clostridium</span></span> species other than <span class="Italics"><span class="Emphasis">Clostridium perfringens</span></span>): 600 to 1200 mg/day in 2, 3 or 4 equal doses.</p>
<p>More severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, particularly those due to proven or suspected <span class="Italics"><span class="Emphasis">Bacteroides fragilis</span></span>, <span class="Italics"><span class="Emphasis">Peptococcus species</span></span>, or <span class="Italics"><span class="Emphasis">Clostridium</span></span> species other than <span class="Italics"><span class="Emphasis">Clostridium perfringens</span></span>: 1200 to 2700 mg/day in 2, 3 or 4 equal doses.</p>
<p>For more serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, these doses may have to be increased. </p>
<p>In life-threatening situations due to either aerobes or anaerobes these doses may be increased.Â  Doses of as much as 4800 mg daily have been given intravenously to adults. See <span class="Bold Italics"><span class="Emphasis"><span class="Bold Italics"><span class="Emphasis">Dilution and Infusion </span></span></span></span><span class="Bold Italics"><span class="Emphasis"><span class="Bold Italics"><span class="Emphasis">Rates</span></span></span></span> below.</p>
<p>Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusion as follows:</p>
<table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">To maintain serum</span></span></p>
<p><span class="Bold"><span class="Emphasis">clindamycin levels</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">Rapid infusion</span></span></p>
<p><span class="Bold"><span class="Emphasis">rate</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">Maintenance</span></span></p>
<p><span class="Bold"><span class="Emphasis">infusion rate</span></span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">Above 4 mcg/mL</p>
<p>Above 5 mcg/mL</p>
<p>Above 6 mcg/mL</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">10 mg/min for 30 min</p>
<p>15 mg/min for 30 min</p>
<p>20 mg/min for 30 min</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">0.75 mg/min</p>
<p>1 mg/min</p>
<p>1.25 mg/min</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="b0e1abd9-476e-474a-b323-a271ef3cc597"></a><a name="section-10.2"></a><p></p>
<h2>Neonates (less than 1 month)<br>
</h2>
<p class="First">15 to 20 mg/kg/day in 3 to 4 equal doses.Â  The lower dosage may be adequate for small prematures.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="fa1a4713-cac1-4ec1-8d7e-a59942366828"></a><a name="section-10.3"></a><p></p>
<h2>Pediatric Patients (1 month of age to 16 years)<br>
</h2>
<p class="First">Parenteral IV administration: 20 to 40 mg/kg/day in 3 or 4 equal doses.Â  The higher doses would be used for more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.Â  As an alternative to dosing on a body weight basis, pediatric patients may be dosed on the basis of square meters body surface: 350 mg/m<span class="Sup">2</span>/day for serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and 450 mg/m<span class="Sup">2</span>/day for more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Parenteral therapy may be changed to oral clindamycin flavored granules (clindamycin palmitate hydrochloride) or clindamycin capsules (clindamycin hydrochloride) when the condition warrants and at the discretion of the physician.</p>
<p>In cases of Î²-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, treatment should be continued for at least 10 days.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="a984c173-8287-44b9-a159-69a2e62d621e"></a><a name="section-10.4"></a><p></p>
<h2>Dilution and Infusion Rates<br>
</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Clindamycin Injection, USP must be diluted prior to IV administration.Â  The concentration of clindamycin in diluent for infusion</span></span><span class="Bold"><span class="Emphasis"> should not exceed 18 mg per mL.Â  Infusion rates should </span></span><span class="Bold"><span class="Emphasis">not exceed 30 mg per minute.Â  </span></span>The usual infusion dilutions and rates are as follows:</p>
<table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Bold"><span class="Emphasis">Dose</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Bold"><span class="Emphasis">Diluent</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Bold"><span class="Emphasis">Time</span></span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">300 mg</p>
<p>600 mg</p>
<p>900 mg</p>
<p>1200 mg</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">50 mL</p>
<p>50 mL</p>
<p>50 to 100 mL</p>
<p>100 mL</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First">10 min</p>
<p>20 min</p>
<p>30 min</p>
<p>40 min</p>
</td>
</tr>
</tbody>
</table>
<p>Administration of more than 1200 mg in a single 1-hour infusion is not recommended. </p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ca8d34e8-6472-476b-a1cb-2b0e1364536a"></a><a name="section-10.5"></a><p></p>
<h2>Dilution and Compatibility<br>
</h2>
<p class="First">Physical and biological compatibility studies monitored for 24 hours at room temperature have demonstrated no inactivation or incompatibility with the use of Clindamycin Injection, USP in IV solutions containing sodium chloride, glucose, calcium or potassium, and solutions containing vitamin B complex in concentrations usually used clinically.Â  No incompatibility has been demonstrated with the antibiotics cephalothin, kanamycin, gentamicin, penicillin or carbenicillin.</p>
<p>The following drugs are physically incompatible with clindamycin phosphate: ampicillin sodium, phenytoin sodium, barbiturates, aminophylline, calcium gluconate, and magnesium sulfate.</p>
<p>The compatibility and duration of stability of drug admixtures will vary depending on concentration and other conditions. </p>
<p>For current information regarding compatibilities of clindamycin phosphate under specific conditions, please visit <span class="Underline"><span class="Emphasis">www.APPpharma.com</span></span> or call our medical information and safety department toll-free at 1-800-551-7176.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dc5eeeab-2ba1-48f2-ae3f-9ef91a7bcf7f"></a><a name="section-10.6"></a><p></p>
<h2>Physico-Chemical Stability of Diluted Solutions of Clindamycin<br>
</h2>
<p class="First">Room temperature: 6, 9 and 12 mg/mL (equivalent to clindamycin base) inÂ  5% Dextrose Injection, 0.9% Sodium Chloride Injection, or Lactated Ringers Injection in glass bottles or minibags, demonstrated physical and chemical stability for at least 16 days at 25Â°C.Â  Also 18 mg/mL (equivalent to clindamycin base) in 5% Dextrose Injection, in minibags, demonstrated physical and chemical stability for at least 16 days at 25Â°C.</p>
<p>Refrigeration: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in 5% Dextrose Injection, 0.9% Sodium Chloride Injection, or Lactated Ringers Injection in glass bottles or minibags, demonstrated physical and chemical stability for at least 32 days at 4Â°C.</p>
<p>IMPORTANT: This chemical stability information in no way indicates that it would be acceptable practice to use this product well after the preparation time. Good professional practice suggests that compounded admixtures should be administered as soon after preparation as is feasible.</p>
<p>Frozen: 6, 9 and 12 mg/mL (equivalent to clindamycin base) in 5% Dextrose Injection, 0.9% Sodium Chloride Injection, or Lactated Ringers Injection in minibags demonstrated physical and chemical stability for at least eight weeks at -10Â°C. </p>
<p>Frozen solutions should be thawed at room temperature and not refrozen.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="bcd1611e-f14e-43df-ac8b-c0f038bb41db"></a><a name="section-11"></a><p></p>
<h1>DIRECTIONS FOR DISPENSING AND PROPER USE OF PHARMACY BULK PACKAGE<br>
</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Pharmacy Bulk Package</span></span> â€“ <span class="Bold"><span class="Emphasis">Not for Direct Infusion</span></span></p>
<p>The Pharmacy Bulk Package is for use in a Pharmacy Admixture Service only under a laminar flow hood.Â  The exposed closure should be swabbed with a suitable asceptic solution.Â  Entry into the vial should be made with a small diameter sterile transfer set or other small diameter sterile dispensing device, and contents dispensed in aliquots using aseptic technique. Multiple entries with a needle and syringe are not recommended.Â  AFTER ENTRY USE ENTIRE CONTENTS OF VIAL PROMPTLY. ANY UNUSED PORTION MUST BE DISCARDED WITHIN <span class="Bold"><span class="Emphasis">4 HOURS</span></span> AFTER INITIAL ENTRY.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="d1d6c965-9219-49ec-8134-5ee93abf8483"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Clindamycin Injection, USP, in the Pharmacy Bulk Package, supplied as clindamycin phosphate equivalent to clindamycin 150 mg/mL, is available as:</p>
<table>
<colgroup>
<col align="left">
<col align="left">
<col align="left">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">Product</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First"><span class="Bold"><span class="Emphasis">Volume</span></span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">28260</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">63323-282-60</p></td>
<td class="Botrule Lrule Rrule Toprule" align="left"><p class="First">60 mL</p></td>
</tr>
</tbody>
</table>
<p>Packaged individually.</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [see USP Controlled Room Temperature].</p>
<p><span class="Bold"><span class="Emphasis">Do not refrigerate.</span></span></p>
<p>Vial stoppers do not contain natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e3ab9c6a-498a-4c5a-8108-7900250c218d"></a><a name="section-13"></a><p></p>
<h1>ANIMAL TOXICOLOGY</h1>
<p class="First">One year oral toxicity studies in Spartan Sprague-Dawley rats and beagle dogs at dose levels up to 300 mg/kg/day (approximately 1.1 and 3.6 times the highest recommended adult human dose based on mg/m<span class="Sup">2</span>, respectively) have shown clindamycin to be well tolerated.Â  No appreciable difference in pathological findings has been observed between groups of animals treated with clindamycin and comparable control groups.Â  Rats receiving clindamycin hydrochloride at 600 mg/kg/day (approximately 2.1 times the highest recommended adult human dose based on mg/m<span class="Sup">2</span>) for six months tolerated the drug well; however, dogs dosed at this level (approximately 7.2 times the highest recommended adult human dose based on mg/m<span class="Sup">2</span>) <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span>, would not eat, and lost weight.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="c1bb406e-5107-4450-81fd-748ce93433d4"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<ol>
<li>Smith RB, Phillips JP: Evaluation of CLEOCIN HCl and CLEOCIN Phosphate in an Aged Population. Upjohn TR 8147-82-9122-021, December 1982.</li>
<li>Bauer AW, Kirby WMM, Sherris JC, Turck M; Antibiotic susceptibility testing by a standardized single disk method. <span class="Italics"><span class="Emphasis">Am. J. Clin. Path</span></span>., <span class="Bold"><span class="Emphasis">45</span></span>:493-496, 1966. Standardized Disk Susceptibility Test, <span class="Italics"><span class="Emphasis">Federal Register</span></span>, <span class="Bold"><span class="Emphasis">37</span></span>:20527-29, 1972.</li>
<li>National Committee for Clinical Lab. Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria â€“ Second Edition; Tentative Standard. NCCLS publication M11-T2. Villanova, PA; NCCLS; 1988.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="d41d8550-4146-46d7-b3a6-ef8c2c5e8116"></a><a name="section-15"></a><p></p>
<h1></h1>
<p class="First"><img alt="app-logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd1c1648-4733-4233-8337-469fe11bd0cb&amp;name=clindamycin-injection-usp-(pbp)-figure-2.jpg"></p>
<p>45985B</p>
<p>Revised: April 2008</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ae931dc4-5288-4f08-ad2d-7dbf603c2a59"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Clindamycin Pharmacy Bulk Package Hanging Vial Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-282-60</p>
<p>28260</p>
<p><span class="Bold"><span class="Emphasis">CLINDAMYCIN INJECTION, USP</span></span></p>
<p>PHARMACY BULK PACKAGE - NOT FOR DIRECT INFUSION</p>
<p><span class="Bold"><span class="Emphasis">9 grams/60 mL (150 mg/mL)</span></span></p>
<p>For Intravenous Use</p>
<p>Dilute before IV Use*</p>
<p><span class="Bold"><span class="Emphasis">9 grams/60 mL</span></span></p>
<br><br><p><img alt="28260-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd1c1648-4733-4233-8337-469fe11bd0cb&amp;name=clindamycin-injection-usp-(pbp)-figure-3.jpg"></p>
<br><br><p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Clindamycin Pharmacy Bulk Package Hanging Vial Carton Panel</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-282-60</p>
<p>28260</p>
<p><span class="Bold"><span class="Emphasis">CLINDAMYCIN INJECTION, USP</span></span></p>
<p>PHARMACY BULK PACKAGE - NOT FOR DIRECT INFUSION</p>
<p><span class="Bold"><span class="Emphasis">9 grams/60 mL (150 mg/mL)</span></span></p>
<p>For Intravenous Use</p>
<p>Dilute before IV Use*</p>
<p>Rx only</p>
<p><span class="Bold"><span class="Emphasis">One</span></span> Vial </p>
<br><p><img alt="28260-carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd1c1648-4733-4233-8337-469fe11bd0cb&amp;name=clindamycin-injection-usp-(pbp)-figure-4.jpg">Â </p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CLINDAMYCINÂ 		
					</strong><br><span class="contentTableReg">clindamycin phosphate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-282</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLINDAMYCIN PHOSPHATE</strong> (CLINDAMYCIN) </td>
<td class="formItem">CLINDAMYCIN PHOSPHATE</td>
<td class="formItem">150Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">0.5Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">9.45Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-282-60</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 mL in 1.0 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065346</td>
<td class="formItem">11/22/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>APP Pharmaceuticals, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">APP Pharmaceuticals, LLC (840771732)</td>
<td class="formItem"></td>
<td class="formItem">840771732</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bd1c1648-4733-4233-8337-469fe11bd0cb</div>
<div>Set id: bd1c1648-4733-4233-8337-469fe11bd0cb</div>
<div>Version: 1</div>
<div>Effective Time: 20091211</div>
</div>
</div>Â <div class="DistributorName">APP Pharmaceuticals, LLC</div></p>
</body></html>
